Search research articles
Contact Us
Filters
Showing results (71-80 of 174) with videos related to
Page
of 18
Sort By:
Pharmacoeconomics
|
March 6, 2007
Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods
Diego F Ossa, Andrew Briggs, Emma McIntosh, et al.
BMJ (Clinical Research Ed.)
|
January 31, 2004
Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment
Mark Sculpher, Stirling Bryan, Pat Fry, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 30, 2010
Eliciting distributions to populate decision analytic models
Laura Bojke, Karl Claxton, Yolanda Bravo-Vergel, et al.
Pharmacoeconomics
|
June 19, 2021
Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies
Ana Duarte, Simon Walker, Andrew Metry, et al.
Journal of Evaluation in Clinical Practice
|
April 22, 2020
Real-world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non-valvular atrial fibrillation patients in England
Ameet Bakhai, Hans Petri, Farnaz Vahidnia, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
September 15, 2005
Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model
Neil Hawkins, David Epstein, Michael Drummond, et al.
Applied Health Economics and Health Policy
|
March 22, 2026
Insights from Financial Economics to Value Healthcare Investments that Reduce System-Level Risks: Example of Disease Elimination and Eradication
Megha Rao, Mark Freeman, Jacco Thijssen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 30, 2016
Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?
Sophie Whyte, Simon Dixon, Rita Faria, et al.
Rheumatology (Oxford, England)
|
August 24, 2011
Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis
Laura Bojke, David Epstein, Dawn Craig, et al.
Journal of Health Services Research & Policy
|
February 9, 2013
Understanding Harris' understanding of CEA: is cost effective resource allocation undone?
Richard Edlin, Christopher McCabe, Jeff Round, et al.
Page
of 18
Search research articles
Search
Showing results (71-80 of 174) with videos related to
Sort By:
Page
of 18
Pharmacoeconomics
|
March 6, 2007
Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods
Diego F Ossa, Andrew Briggs, Emma McIntosh, et al.
BMJ (Clinical Research Ed.)
|
January 31, 2004
Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment
Mark Sculpher, Stirling Bryan, Pat Fry, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 30, 2010
Eliciting distributions to populate decision analytic models
Laura Bojke, Karl Claxton, Yolanda Bravo-Vergel, et al.
Pharmacoeconomics
|
June 19, 2021
Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies
Ana Duarte, Simon Walker, Andrew Metry, et al.
Journal of Evaluation in Clinical Practice
|
April 22, 2020
Real-world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non-valvular atrial fibrillation patients in England
Ameet Bakhai, Hans Petri, Farnaz Vahidnia, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
September 15, 2005
Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model
Neil Hawkins, David Epstein, Michael Drummond, et al.
Applied Health Economics and Health Policy
|
March 22, 2026
Insights from Financial Economics to Value Healthcare Investments that Reduce System-Level Risks: Example of Disease Elimination and Eradication
Megha Rao, Mark Freeman, Jacco Thijssen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 30, 2016
Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?
Sophie Whyte, Simon Dixon, Rita Faria, et al.
Rheumatology (Oxford, England)
|
August 24, 2011
Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis
Laura Bojke, David Epstein, Dawn Craig, et al.
Journal of Health Services Research & Policy
|
February 9, 2013
Understanding Harris' understanding of CEA: is cost effective resource allocation undone?
Richard Edlin, Christopher McCabe, Jeff Round, et al.
Page
of 18